Key Takeaways

• The DEA and HHS have extended telemedicine flexibilities until December 31, 2026, to maintain patient access to care.
• Healthcare providers can prescribe Schedule II-V controlled substances via telemedicine after an initial in-person evaluation.
• The extension addresses concerns about a potential “telemedicine cliff,” which could disrupt access to necessary medications.

Telemedicine Flexibilities Extended

The U.S. Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) have announced a Fourth Temporary Extension of telemedicine prescribing flexibilities. This extension, effective until December 31, 2026, aims to avert an abrupt end to remote access to medications, often referred to as the “telemedicine cliff.”

Under this extension, healthcare providers are allowed to continue prescribing Schedule II–V controlled substances remotely, provided there has been at least one initial in-person evaluation. This flexibility is crucial for ensuring patient access to essential medications, which range from high-abuse drugs like opioids and stimulants to lower-risk medications such as certain cough medicines.

Initially introduced in March 2020 amid the COVID-19 public health emergency, these telemedicine regulations allowed for remote prescribing of controlled substances without prior in-person visits. The current rules sustain these practices while maintaining that some Schedule II medications might still require an initial in-person evaluation. Notably, audio-only telemedicine visits are still permissible for prescribing certain Schedule III–V narcotics approved for opioid use disorder treatment without prior evaluations.

The DEA and HHS collaborated on this extension in response to concerns from patients and healthcare providers about the potential negative consequences of terminating these flexibilities without a permanent solution. They acknowledged communications expressing worries that discontinuing the existing rules would drastically limit access to necessary controlled substances for patients who haven’t had recent in-person evaluations.

The ongoing extension aims to ensure continuity in patient care while the federal government considers long-term regulations for telehealth and controlled substance prescribing, preventing unnecessary disruptions in treatment. The agencies emphasized the widespread implications of a “telemedicine cliff” and the urgent need for a balanced approach to safeguard access to care.

For now, the extension provides a vital bridge during the transition period as the landscape of telehealth continues to evolve.

The content above is a summary. For more details, see the source article.